Circulating MicroRNAs as Novel Biomarkers in Risk Assessment and Prognosis of Coronary Artery Disease.

IF 3.2 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS

European Cardiology Review Pub Date : 2022-03-07 eCollection Date: 2022-02-01 DOI:10.15420/ecr.2021.47

Chiara Vavassori, Eleonora Cipriani, Gualtiero Ivanoe Colombo

{"title":"Circulating MicroRNAs as Novel Biomarkers in Risk Assessment and Prognosis of Coronary Artery Disease.","authors":"Chiara Vavassori, Eleonora Cipriani, Gualtiero Ivanoe Colombo","doi":"10.15420/ecr.2021.47","DOIUrl":null,"url":null,"abstract":"<p><p>Coronary artery disease is among the leading causes of death worldwide. Nevertheless, available cardiovascular risk prediction algorithms still miss a significant portion of individuals at-risk. Thus, the search for novel non-invasive biomarkers to refine cardiovascular risk assessment is both an urgent need and an attractive topic, which may lead to a more accurate risk stratification and/or prognostic score definition for coronary artery disease. A new class of such non-invasive biomarkers is represented by extracellular microRNAs (miRNAs) circulating in the blood. MiRNAs are non-coding RNA of 22-25 nucleotides in length that play a significant role in both cardiovascular physiology and pathophysiology. Given their high stability and conservation, resistance to degradative enzymes, and detectability in body fluids, circulating miRNAs are promising emerging biomarkers, and specific expression patterns have already been associated with a wide range of cardiovascular conditions. In this review, an overview of the role of blood miRNAs in risk assessment and prognosis of coronary artery disease is given.</p>","PeriodicalId":45957,"journal":{"name":"European Cardiology Review","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2022-03-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/fd/ecr-17-e06.PMC8924954.pdf","citationCount":"6","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Cardiology Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15420/ecr.2021.47","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/2/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}

引用次数: 6

Abstract

Coronary artery disease is among the leading causes of death worldwide. Nevertheless, available cardiovascular risk prediction algorithms still miss a significant portion of individuals at-risk. Thus, the search for novel non-invasive biomarkers to refine cardiovascular risk assessment is both an urgent need and an attractive topic, which may lead to a more accurate risk stratification and/or prognostic score definition for coronary artery disease. A new class of such non-invasive biomarkers is represented by extracellular microRNAs (miRNAs) circulating in the blood. MiRNAs are non-coding RNA of 22-25 nucleotides in length that play a significant role in both cardiovascular physiology and pathophysiology. Given their high stability and conservation, resistance to degradative enzymes, and detectability in body fluids, circulating miRNAs are promising emerging biomarkers, and specific expression patterns have already been associated with a wide range of cardiovascular conditions. In this review, an overview of the role of blood miRNAs in risk assessment and prognosis of coronary artery disease is given.

Abstract Image

查看原文本刊更多论文

循环microrna作为冠状动脉疾病风险评估和预后的新生物标志物。

冠状动脉疾病是全世界的主要死亡原因之一。然而，现有的心血管风险预测算法仍然遗漏了很大一部分高危人群。因此，寻找新的无创生物标志物来完善心血管风险评估是一个迫切需要和有吸引力的话题，这可能导致冠状动脉疾病更准确的风险分层和/或预后评分定义。一类新的非侵入性生物标志物是血液中循环的细胞外microRNAs (miRNAs)。mirna是长度为22-25个核苷酸的非编码RNA，在心血管生理和病理生理中都起着重要作用。鉴于其高稳定性和保守性，对降解酶的抗性以及在体液中的可检测性，循环mirna是有前途的新兴生物标志物，并且特定的表达模式已经与广泛的心血管疾病相关。本文就血液mirna在冠状动脉疾病风险评估和预后中的作用进行综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊